Confirmation of Strategic Investment by Maxhealth

Rex Bionics Plc

("Rex Bionics" or the "Company")

Confirmation of Strategic Investment by Maxhealth

Application for Further Admission

05 August 2016: Rex Bionics plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is today pleased to announce that Maxhealth Medicine Co. Ltd has now deposited £1 million in escrow in relation to its subscription for 3,333,333 ordinary shares at 30p each. This £1 million will be released from escrow and become available to the Company upon admission of the shares to trading. The Company has also received commitment for a further subscription of £225,000 for 750,000 ordinary shares of 30p each from Hunter Hall Investment Management Limited.

Based in Wuxi, Jiangsu province, Maxhealth is a Chinese distributor of high technology medical products including the REX robotic mobility system, as well as products from other leading companies - including Baxter, Olympus and Straumann.

Maxhealth is an associate of MAAB Group, with whom Rex Bionics signed a distribution agreement for China on 20 July 2015. A Memorandum of Understanding between Rex Bionics, Maxhealth and MAAB Group was signed in April 2016, triggering local sales and distribution activity. Clinical specialists have been trained and have started to work with potential customers with the two REX units that have been imported to date, demonstrating the value that REX can provide.

Crispin Simon, Chief Executive, said "China is one of our two principal target markets - the other being the US. We are pleased with the start we have made with our partners in China and delighted by the display of confidence that this strategic investment by Maxhealth represents."

Tony Miao, Maxhealth Chief Executive, said "We are pleased to be able to make this investment and believe that the REX will be very successful in China".

Application has been made for admission of a further 4,083,333 ordinary shares which is expected to take place at 8.00 a.m. on 10 August 2016. Following this, the total number of ordinary shares in the Company will be 25,513,859. The Company does not hold any common shares in treasury and this figure may therefore be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.

The subscriptions announced today of, in total, £1.22 million together with the subscriptions of, in total, £1.08 million for shares that were admitted on 2 August 2016 mean that the total amount which will be raised by the Company through this fundraising is £2.30 million, through the issue of 7,683,333 ordinary shares at 30p each.

A copy of this announcement has been posted on the Company's website at www.rexbionics.com/.

For further information please contact:

Rex Bionics Plc

Crispin Simon, Chief Executive Officer

+44 (0) 781 086 6386

Peter Worrall, Chief Financial Officer

+44 (0)1428 645416

Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior/ Stewart Wallace / Ben Maddison

+44 (0) 20 7710 7600

Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh

[email protected]

+44 (0) 203 709 5700